Methylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathways

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Lim, Eun Joung ^a   Hong, Dae Young ^b   Park, Jin Hee ^a   Joung, Youn Hee ^a   Darvin, Pramod ^a   Kim, Sang Yoon ^a   Na, Yoon Mi ^a   Hwang, Tae Sook ^a   Ye, Sang Kyu ^c   Moon, Eon Soo ^a   Cho, Byung Wook ^d   Park, Kyung ^e   Lee, Hak Kyo ^e   Park, Taekyu ^f   Yang, Young Mok ^a  

^a Konkuk University School of Medicine   (South Korea)

^b Konkuk University Hospital   (South Korea)

^c Seoul National University   (South Korea)

^d Pusan National University   (South Korea)

^e Hankyong National University   (South Korea)

^f Konkuk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL SULFONE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90ALPHA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SOMATOMEDIN C; STAT3 PROTEIN; STAT5B PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; DIMETHYL SULFOXIDE; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN, HUMAN; STAT5 PROTEIN; STAT5B PROTEIN, HUMAN; SULFONE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; BREAST TUMOR; CELL MOTION; CELL STRAIN COS1; CELL SURVIVAL; CERCOPITHECUS; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENETICS; IC 50; METABOLISM; PROMOTER REGION; PROTEIN BINDING; TUMOR CELL LINE; TUMOR VOLUME;

MUS; MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; COS CELLS; DIMETHYL SULFOXIDE; DOWN-REGULATION; FEMALE; GENE EXPRESSION; HUMANS; INHIBITORY CONCENTRATION 50; MICE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECEPTOR, IGF TYPE 1; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; SULFONES; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859222403     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033361     Document Type: Article

References (57)

1. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, et al. (2009) Triple-negative breast cancer-current status and future directions. Ann Oncol 20: 1913-27.
2. Anders CK, Carey LA, (2009) Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 9(Suppl 2) pp. S73-S81.
3. Ismail-Khan R, Bui MM, (2010) A review of triple-negative breast cancer. Cancer Control 17 (3): 173-6.
4. Chen JQ, Russo J, (2009) ERα-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches. Biochem Biophys Acta 1796: 162-75.
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-82.
6. Yarden Y, Sliwkowski MX, (2001) Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2: 127-37.
7. Moasser MM, (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26: 6469-87.
8. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, et al. (2004) Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 10: 2751-60.
9. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, et al. (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9: 1603-14.
10. Kraus WL, Katzenellenbogen BS, (1993) Regulation of progesterone receptor gene expression and growth in the rat uterus: modulation of estrogen actions by progesterone and sex steroid hormone antagonists. Endocrinology 132: 2371-9.
11. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, et al. (1995) Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 9: 2266-78.
12. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, et al. (2000) Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? J Steroid Biochem Mol Biol 74: 255-9.
13. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, et al. (1992) Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10: 1284-91.
14. Fisher BJ, Perera FE, Cooke AL, Opeitum A, Stitt L, (1998) Long-term follow-up of axillary node positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence. Int J Radiat Oncol Biol Phys 42: 117-23.
15. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, et al. (2005) Estrogen receptor - positive, progesterone receptor - negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97: 1254-61.
16. Black R, Prescott R, Bers K, Hawkins A, Stewart H, et al. (1983) Tumor cellularity, oestrogen receptors and prognosis in breast cancer. Clin Oncol 9: 311-8.
17. Zhang HJ, Kennedy BJ, Kiang DT, (1984) Thymidine kinase as a predictor of response to chemotherapy in advanced breast cancer. Breast Cancer Res Treat 4: 221-5.
18. Dabrosin C, Margetts PJ, Gauldie J, (2003) Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer. Int J cancer 107: 535-40.
19. Ferrara N, Gerber HP, LeCouter J, (2003) The biology of VEGF and its receptors. Nat Med 9: 669-76.
20. Matsumoto T, Claesson-Welsh L, (2001) VEGF receptor signal transduction. Sci STKE 2001 (112): RE21.
21. Kimura H, Weisz A, Ogura T, Yoshiaki H, Yukiko K, et al. (2001) Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J Biol Chem 276: 2292-8.
22. Klagsbrun M, D'Amore PA, (1996) Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 7: 259-70.
23. Chapman RS, Lourenco P, Tonner E, Flint D, Selbert S, et al. (2000) The role of STAT3 in apoptosis and mammary gland involution. Conditional deletion of STAT 3. Adv Exp Med Biol 480: 129-38.
24. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL, (2003) Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 9 (2): 594-600.
25. Jung JE, Lee HG, Cho IH, Chung DH, Yang YM, et al. (2005) STAT3 is a potential modulator of HIF-1 mediated VEGF expression in human renal carcinoma cells. FASEB J 19 (10): 1296-8.
26. Niu G, Wright KL, Huang M, Song L, Haura E, et al. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-8.
27. Joung YH, Lee MY, Lim EJ, Kim MS, Hwang TS, et al. (2007) Hypoxia activates the IGF - 1 expression through STAT5b in human HepG2 cells. Biochem Biophys Res Commun 358: 733-8.
28. Joung YH, Lim EJ, Kim MS, Lim DS, Yoon SY, et al. (2008) Enhancement of hypoxia-induced apoptosis of human breast cancer cell via stat5b by momilactone B. Int J Oncol 33: 477-84.
29. Lim EJ, Joung YH, Jung SM, Park SH, Park JH, et al. (2010) Hemin inhibits cyclin D1 and IGE - 1 expression via STAT5b under hypoxia in ERα - negative MDA - MB 231 breast cancer cells. Int J Oncol 36: 1243-51.
30. Silva Ferreira AC, Rodrigues P, Hogg T, Guedes DP, (2003) Infl{ligature}uence of some technological parameters on the formation of dimethyl sulfide, 2-mercaptoethanol, methionol, and dimethyl sulfone in port wines. J Agric Food Chem 51: 727-32.
31. Rose SE, Chalk JB, Galloway GJ, Doddrell DM, (2000) Detection of dimethyl sulfone in the human brain by in vivo proton magnetic resonance spectroscopy. Magn Reson Imaging 18: 95-8.
32. Engelke UF, Tangerman A, Willemsen MA, Moskau D, Loss S, et al. (2005) Dimethyl sulfone in human cerebrospinal fluid and blood plasma confirmed by one-dimensional 1H and two dimensional 1 H- 13 C NMR. NMR Biomed 18: 331-6.
33. Morton JI, Siegel BV, (1986) Effects of oral dimethyl sulfoxide and dimethyl sulfone on murine autoimmune lymphoproliferative disease. Proc Soc Exp Biol Med 183: 227-30.
34. Horvath K, Noker PE, Somfai-Relle S, Glavits R, Financsek I, et al. (2002) Toxicity of methylsulfonylmethane in rats. Food Chem Toxicol 40: 1459-62.
35. Kim LS, Axelrod LJ, Howard P, Buratovich N, Waters RF, (2006) Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. OsteoArthritis Cartilage 14: 286-94.
36. Barrager E, Veltmann JR, Jr, Schauss AG, Schiller RN, (2002) A multicentered, open-label trial on the safety and efficacy of methyl sulfonyl methane in the treatment of seasonal allergic rhinitis. J Altern Complement Med 8: 167-73.
37. Beilke MA, Collins-Lech C, Sohnle PG, (1987) Effects of dimethyl sulfoxide on the oxidative function of human neutrophils. J Lab Clin Med 110: 91-6.
38. Jacob SW, Appleton J, (2003) MSM: The definitive guide, a comprehensive review of the science and therapeutics of methylsulfunylmethane. Topanga, CA: Freedom Press 107-21.
39. Childs SJ, (1994) Dimethyl sulfone (DMSO2) in the treatment of interstitial cystitis. Urol Clin North Am 21: 85-8.
40. Caron JM, Bannon M, Rosshirt L, Luis J, Montaegudo L, et al. (2010) Methyl sulfone induces loss of metastatic properties and reemergence of normal phenotype in a metastatic cloudman S-91 (M3) murine melanoma cell line. PLoS ONE 5 (8): e11788.
41. Park SH, Yamashita H, Rui H, Waxman DJ, (2001) Serine phosphorylation of GH-activated signal transducer and activator of transcription 5a (STAT-5a) and 5b: Impact on STAT5 transcriptional activity. Mol Endocrinol 15: 2157-71.
42. Yamashita H, Nishio M, Fujii Y, Iwase H, (2004) Dominant negative STAT5 inhibits growth and induces apoptosis in T47D-derived tumors in nude mice. Cancer Sci 95: 662-5.
43. Battle TE, Frank DA, (2002) The role of STATs in apoptosis. Curr Mol Med 2: 381-92.
44. Tweardy D, Chang JC, (2011) Stat5: From breast development to cancer progression, prediction and progression. J Clin Oncol 29: 2443-7.
45. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, et al. (1997) Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 11: 179-86.
46. Weaver AM, Silva CM, (2007) Signal transducers and activator of transcription 5b (STAT5b): a new target of breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6). Breast Cancer Res 9 (6): R79.
47. Bernaciak TM, Zareno J, Parsons JT, Silva CM, (2009) A novel role for signal transducer and activator of transcription 5b (STAT5b) in beta-integrin mediated human breast cancer cell migration. Breast Cancer Res 11: R52.
48. Joung YH, Lim EJ, Lee MY, Park JH, Ye SK, et al. (2005) Hypoxia activates the cyclin D1 promoter via the jak2/STAT5b pathway in breast cancer cells. Exp Mol Med 37: 353-64.
49. Buettner R, Mora LB, Jove R, (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-54.
50. Tian X, Aruva MR, Zhang K, Shanthly N, Cardi CA, et al. (2007) PET imaging of CCND1 mRNA in human MCF7 estrogen receptor positive breast cancer xenografts with oncogene-specific [64Cu] chelator-peptide nucleic acid-IGF1 analog radiohybridization probes. J Nucl Med 48: 1699-707.
51. Yi HK, Hwang PH, Yang DH, Kang CW, Lee DY, (2001) Expression of insulin-like growth factors (IGFs) and the IGF binding proteins in human gastric cancer cells. Eur J Cancer 37: 2257-63.
52. Hwang PH, Kim SY, Lee JC, Kim SJ, Yi HK, et al. (2005) PTEN/MMAC1 enhances the growth inhibition by anticancer drugs with downregulation of IGF - II expression in gastric cancer cells. Exp Mol Med 37: 391-8.
53. Werner H, Karnieli E, Rauscher FJ, Leroith D, (1996) Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 93: 8318-23.
54. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, et al. (2004) Inhibition of the insulin-like gorwth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies and solid tumors. Cancer Cell 5: 221-30.
55. Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, et al. (2010) Triple negative breat cancer: present challenges and new perspectives. Mol Oncol 4: 209-29.
56. Fowler AM, Alarid ET, (2007) Amping up estrogen receptors in breast cancer. Breast Cancer Res 9: 305.
57. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ, (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to Trastuzumab resistance of breast cancer cells. Cancer Res 65: 11118-28.